Vaginal dehydroepiandrosterone (DHEA) may improve sexual function, without negative systemic effects, in women with breast and gynecologic cancer with vaginal and sexual-related complaints.
Controversies in treatment-induced alopecia and hair adverse events were brought to the attention of the medical community in a presentation by Mario Lacouture, MD, at the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology 2014 annual meeting.
Reactive management and attention to possible infection is usually sufficient to treat dermatologic toxicities associated with targeted cancer therapies, said Barbara Burtness, MD, professor of medical oncology at Fox Chase Cancer Center in Philadelphia, Pennsylvania.
About 50% of cancer patients —90% in some subsets—develop cancer- or chemotherapy-related anemia.
NEPA, a fixed-dose combination of netupitant and palonosetron, proved more effective than palonosetron alone in preventing chemotherapy-induced nausea and vomiting (CINV) in a large multinational study of 1455 patients, according to data presented at the 2013 San Antonio Breast Cancer Symposium.
Data from a large population of patients with multiple myeloma receiving zoledronic acid infusions indicate that osteonecrosis of the jaw (ONJ) remains a significant complication, especially for patients who receive it for prolonged periods, investigators from Greece reported at the 2013 American Society of Hematology annual meeting.
Subsets of patients with colon cancer may benefit from increased surveillance for toxicities associated with adjuvant FOLFOX (leucovorin, fluorouracil, oxaliplatin) treatment, Canadian researchers suggest, based on their detailed analysis of the toxicity profile of this common regimen and their identification of factors that predict toxicity.
Cancer anorexia-cachexia syndrome (CACS) is underrecognized and underreported in patients with advanced lung cancer receiving routine clinical care, according to a retrospective, single-institution study presented at the 2013 Annual Meeting of the Multinational Association of Supportive Care in Cancer (MASCC).
A novel fixed-dose combination of netupitant and palonosetron, referred to as NEPA, was found to be highly effective in preventing chemotherapy-induced nausea and vomiting in 2 studies presented at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting.
Dermatologic adverse events are frequently reported in patients treated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), dual EGFR/human epidermal growth factor receptor 2 (HER2) blockers, and ErbB family blockers.
Page 3 of 8
Results 21 - 30 of 78
Results 21 - 30 of 78